A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to estimate the effect of rifampin on the single dose PK of PF-06463922.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Rifampin

Criteria

Inclusion Criteria:

• Healthy female subjects of non-childbearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive

• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease

• Any condition possibly affecting drug absorption

• Positive urine drug screen

• History of HIV, Hep B or Hep C

• History of regular alcohol consumption

• History of cardiac arrhythmia, history of AV block, history of symptomatic bradycardia, history of QTc prolongation

• History of pancreatitis or hyperlipidemia, elevated lipase